ImmuPharma Historical Cash Flow
| IMM Stock | 1.43 0.04 2.72% |
Analysis of ImmuPharma PLC cash flow over time is an excellent tool to project ImmuPharma PLC future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 955.4 K or Capital Expenditures of 1.9 as it is a great indicator of ImmuPharma PLC ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining ImmuPharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ImmuPharma PLC is a good buy for the upcoming year.
ImmuPharma |
About ImmuPharma Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in ImmuPharma balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ImmuPharma's non-liquid assets can be easily converted into cash.
ImmuPharma PLC Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from ImmuPharma PLC's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into ImmuPharma PLC current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuPharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, ImmuPharma PLC's Other Non Cash Items is projected to increase significantly based on the last few years of reporting. The current year's Change To Account Receivables is expected to grow to about 268.6 K, whereas Free Cash Flow is forecasted to decline to (1.4 M).
ImmuPharma PLC cash flow statement Correlations
Click cells to compare fundamentals
ImmuPharma PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ImmuPharma PLC cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.5M) | 4.5M | (4.2M) | (981.6K) | (459.3K) | (436.4K) | |
| Free Cash Flow | (4.3M) | (3.7M) | (4.9M) | (2.5M) | (1.4M) | (1.4M) | |
| Change In Working Capital | (230.9K) | 105.5K | 631.6K | (428.8K) | 469.6K | 493.1K | |
| Begin Period Cash Flow | 4.9M | 1.4M | 5.9M | 1.6M | 667.8K | 634.4K | |
| Other Cashflows From Financing Activities | (2.2M) | (945.3K) | (2.1M) | (803.2K) | (758.6K) | (720.7K) | |
| Other Non Cash Items | 219.6K | 405.2K | 391.6K | 833.2K | 909.9K | 955.4K | |
| Capital Expenditures | 107.1K | 360.3K | 50.9K | 106.0K | 2.0 | 1.9 | |
| Total Cash From Operating Activities | (4.2M) | (3.3M) | (4.8M) | (2.3M) | (1.4M) | (1.4M) | |
| Net Income | (6.3M) | (5.6M) | (6.6M) | (3.0M) | (2.9M) | (3.1M) | |
| Total Cash From Financing Activities | 325.7K | 8.4M | 702.0K | 1.5M | 722.1K | 686.0K | |
| End Period Cash Flow | 1.4M | 5.9M | 1.6M | 667.8K | 208.5K | 198.1K | |
| Total Cashflows From Investing Activities | (2.1M) | (101.4K) | (569.2K) | (50.3K) | (45.3K) | (47.5K) | |
| Depreciation | 88.0K | 171.0K | 114.1K | 117.6K | 37.6K | 35.7K | |
| Other Cashflows From Investing Activities | 12.5K | 5.7K | 41.1K | 651.0 | 585.9 | 556.6 | |
| Stock Based Compensation | 2.0M | 1.6M | 616.4K | 159.9K | 140.2K | 133.2K | |
| Change To Account Receivables | 177.9K | (8.4K) | (265.2K) | (296.4K) | 255.8K | 268.6K | |
| Sale Purchase Of Stock | 4.1M | 10M | 2.7M | 8M | 9.2M | 6.5M | |
| Net Borrowings | (138.9K) | (89.2K) | 1.3M | (723.0K) | (831.4K) | (789.9K) | |
| Change To Netincome | 2.2M | 2.0M | 3.3M | 2.6M | 3.0M | 3.1M | |
| Change To Liabilities | 15.2K | (408.8K) | 113.9K | 896.8K | 1.0M | 1.1M | |
| Issuance Of Capital Stock | 2.7M | 8M | 3.6M | 2.4M | 1.5M | 1.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
The Cash Flow Statement is a financial statement that shows how changes in ImmuPharma balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which ImmuPharma's non-liquid assets can be easily converted into cash.